Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III non-inferiority trial of Hengli versus Botox for crow's feet lines in adults
CTR20240329Phase 3Active
- Sponsor
- Lanzhou Biotechnology Development
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lanbotulinumtoxin-A, botulinum toxin type A in lateral canthal rhytides, sponsored by Lanzhou Biotechnology Development. Started Mar 2024; status: active.
02
Drugs
lanbotulinumtoxin-Abotulinum toxin type A
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on CTR20240329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240329.